BioMarin acquires Inozyme Pharma for $270M to expand rare disease research.

From Yahoo Finance: 2025-05-18 08:17:00

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced a $270 million acquisition of Inozyme Pharma to expand rare disease research. The deal includes INZ-701, an enzyme replacement therapy targeting ENPP1 and ABCC6 deficiencies, expected to close between July and September.

INZ-701 aims to restore inorganic pyrophosphate levels, preventing tissue calcification. Late-stage trial results for ENPP1 deficiency are expected next year, with potential FDA approval by 2027. Analysts view this acquisition as a strategic expansion for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN).

Despite a rare patient pool of around 10,000 globally, experts see commercial potential in the acquisition, expecting it to strengthen BioMarin’s pipeline development. While some analysts praise its strategic fit, others believe it won’t significantly impact BioMarin’s overall market position.

Read more: BioMarin Expands Rare Disease Portfolio with $270M Inozyme Acquisition